Grant agreement ID
101058056
CORDIS
https://cordis.europa.eu/project/id/101058056
Coordinated by
Lucero AB
Funded under
The European Innovation Council (EIC)
Total cost
€ 1 298 712,50
EU contibution
€ 1 298 712,50
Start date
1 January 2023
End date
31 December 2025
Personalised medicine has become a key focus for the pharmaceutical industry as it can address global health challenges, such as strong variations of drug efficacy and toxicity linked to different patient subgroups. A major challenge that pharmaceutical companies still face is the lack of enabling technologies they need to evaluate drug candidates in patients before entering clinical trials.
Lucero enables them to take the next step towards personalised treatments by providing a novel cell-handling platform that combines microfluidics, optical tweezers and artificial intelligence. Our technology is tailored to pre-clinical drug screening procedures for which patient-derived 3D cell cultures have to be automatically selected, isolated, and prepared for drug testing at high throughput speed, in line with their scalability requirements.
